Skip to main content

3 biotech stocks battle the ‘Dendreon Effect’

Dendreon Corp.’s tepid sales report has not only chilled trading in the company’s once-hot stock but has also managed to frost investors in three other biotechs: Savient Pharmaceuticals, Human Genome Sciences and InterMune Inc.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.